SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Singleton who wrote (861)5/25/1998 9:38:00 PM
From: Biomaven  Read Replies (1) of 10280
 
Peter,

I asked a urologist I know slightly about tolterodine. He hasn't used it much yet because it's so new. He said that (unlike oxybutynin) there is often a significant lag before it starts to work. His impression also was that it was meant for a somewhat different population than oxybutynin. He confirmed that oxybutynin's side-effect profile is a significant hindrance to its use.

Sounded to me like there will still be a significant market for an improved oxybutynin.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News